home / stock / lxeo / lxeo news


LXEO News and Press, Lexeo Therapeutics, Inc.

Stock Information

Company Name: Lexeo Therapeutics, Inc.
Stock Symbol: LXEO
Market: NASDAQ
Website: lexeotx.com

Menu

LXEO LXEO Quote LXEO Short LXEO News LXEO Articles LXEO Message Board
Get LXEO Alerts

News, Short Squeeze, Breakout and More Instantly...

LXEO - Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the Leerink Global Health...

LXEO - Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

2026-02-13 17:27:50 ET Lexeo Therapeutics, Inc. (LXEO) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 12:30 PM EST... Read the full article on Seeking Alpha For further details see: Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securit...

LXEO - Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences ...

LXEO - Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company’...

LXEO - Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-14 13:56:06 ET Lexeo Therapeutics, Inc. (LXEO) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcar...

LXEO - US Companies Moving the Markets, Morning edition
Tue, Jan 13, 2026 as of 10.00 am ET

A look at the top 10 most actives in the United States Envirotech Vehicles Inc. (EVTV) rose 442.0% to $2.51 on volume of 760,991,766 shares Oriental Culture Holding LTD (OCG) fell 15.5% to $0.0169 on volume of 452,241,771 shares Mingteng International Corporation Inc. (MTEN) fell 41.9% to $...

LXEO - Buy Recommendation Issued On LXEO By H.C. Wainwright

2026-01-13 06:15:18 ET H.C. Wainwright analyst issues BUY recommendation for LXEO on January 13, 2026 11:15AM ET. The previous analyst recommendation was Buy. LXEO was trading at $8.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...

LXEO - US Companies Moving the Markets, Evening edition
Mon, Jan 12, 2026 as of 4:00 pm ET

A look at the top 10 most actives in the United States Envirotech Vehicles Inc. (EVTV) rose 295.2% to $1.83 on volume of 610,320,780 shares Oriental Culture Holding LTD (OCG) fell 15.0% to $0.017 on volume of 389,655,949 shares Mingteng International Corporation Inc. (MTEN) fell 43.7% to $0...

LXEO - Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript

2026-01-12 12:55:58 ET Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy January 12, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Lexeo Therapeut...

LXEO - Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

LX2020 generally well tolerated across ten participants with no clinically significant complement activation  LX2020 transduction, transcription, and increased protein expression observed across participants with dose-dependent response; mean increase in PKP2 protein of 93% in low-dose c...

Next 10